UCLA to host 14th Annual Brain Tumor Conference
May 9th - 10th, 2014
REGISTRATION INFORMATION INSIDE

Precision Clinical Trials targeting specific molecular features of recurrent gliomas

Lapatinib, an EGFRvIII type II inhibitor, for patients with Glioblastoma Multiforme

IDH1 Mutation Discovery Sparks New Research, Phase I Multicenter trial

Art of the Brain Annual Gala “The Art of Healing with Family Traditions”
Content

03 Director's Message
Letter from Dr. Timothy Cloughesy, Director of the UCLA Neuro-Oncology Program

Research & Clinical Trials
04 Precision Clinical Trials

06 Research Collaboration on Lapatinib

08 IDH1 Mutation Sparks New Research

09 Clinical Trials Now Enrolling
Clinical trials available through UCLA Neuro-Oncology Program

Neuro-Oncology Support
10 Art of the Brain : 14th Annual Gala
"The Art of Healing with Family Traditions"

19 UCLA Neuro-Oncology: Memorial Funds

Brain Tumor Conference
14 UCLA 14th Annual Brain Tumor Conference
UCLA Neuro-Oncology Program to host educational event for patients, caregivers and families.
Registration Deadlines: By Fax & Online - May 6, 2014
By Mail - May 3, 2014

For more information on patient services and clinical trials, visit us at: www.neurooncology.ucla.edu.

To be removed from the mailing list, please email us at neuroonc@ucla.edu or call (310) 206-3610.
Dear Friends,

Brain cancer continues to be one of the most difficult malignancies to treat. The most ideal way to successfully eradicate any malignancy is through early detection and prevention. Unfortunately these options do not presently exist with brain cancer. Therefore, in order to be successful in treating brain cancer, we must do so upon diagnosis. Despite the tremendous advances in neurosurgery, radiation oncology and medical oncology approaches over the years brain cancer remains largely incurable. The ability to sequence the entire human genome has allowed for the detailed molecular characterization of the most malignant form of brain cancer, glioblastoma. These data have provided new insights into how tumors develop and the ability to identify unique molecular lesions in these cancers. If these unique molecular lesions are important for the growth and progression of these tumors, blocking them may lead to tumor control. Importantly the pharmaceutical industry has developing agents to target even the rarest molecular lesions and even in the rarest tumors. The next critical step to realize success at this approach is to identify patient populations at who have these rare molecular lesions and to match them with the appropriate targeting agent. Successful attempts at this approach have been coined “precision medicine.”

In this edition of Breakthroughs we highlight five clinical trials that embody the precision medicine approach. Each of these trials requires the patient’s cancer have the unique molecular feature and, upon confirmation, they are then eligible to be matched with targeting agent in a clinical trial. We are excited to be able to offer these unique and forward thinking trials to our patients.

Our stature as leaders in the field allows us to command these trial opportunities for our patients; however, without the support to our program from generous funders like Art of the Brain, these opportunities would not be possible. Thank you for all of your support that guides us toward the eradication of brain cancer.

Director

Timothy Cloughesy, MD
The advancement of precision medicine is on the horizon, for brain and central nervous system (CNS) cancer patients, as medical researchers probe into new molecular findings and utilize these breakthroughs to research possible treatment options. Gene sequencing in brain tumors has identified certain molecular features of cancer cells that demand clinical research for targeted therapy. Despite standard treatments for brain and CNS cancers that include surgical resection, radiation, and temozolomide chemotherapy, prognosis for high grade gliomas continues to be poor.

The molecular makeup of brain tumors varies widely. Brain tumors are classified by the World Health Organization’s (WHO) classification system, which bases its classification on the specific type of cell the abnormal growth stems from. For example, astrocytomas stem from astrocytic cells and oligodendroglialomas stem from oligodendroglial cells. Further classification grades each tumor type into categories I-IV. Glioblastoma Multiforme grade IV (GBM) is the highest grade of brain tumors. Furthermore, GBM tumors have been found to possess certain gene mutations or amplifications, though not all GBMs are driven by the same genetic alteration. These abnormalities are responsible for its biological behavior, and how they respond to treatment.

With the rise of focus in personalized medicine, come numerous research studies and clinical trials being performed to find new treatment approaches to tackling this disease. The UCLA Neuro-Oncology Program is offering several clinical research trials that target a number of cellular components that have been found to promote tumorigenesis.

BGJ398
One precision clinical trial that is being offered by the UCLA Neuro-Oncology Program is a study focusing on the use of BGJ398, which is a selective and ATP competitive pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. FGFR is part of a pathway that helps cells function normally, and overactivity in this pathway can cause tumor growth. Previous study has shown that some cases of GBM tumors are characterized by the fusion of the FGFR gene and TACC (trans-
forming acidic coiled-coil) gene. Targeting the fusion protein with an FGFR kinase inhibitor prolonged survival in mice with GBM expressing the FGFR-TACC fusion. (Devendra Singh, Joseph Minhow Chan, et al., Science 2012 Sep 7; 337(6099): 1231-5).

The Phase II clinical trial offered at UCLA, sponsored by Novartis, will assess the safety and efficacy of the investigational drug in GBM patients with recurrent tumors that have evidence of FGFR amplification or translocation. BGJ398 functions by binding to the FGFR family of proteins to inhibit the growth of the GBM tumor. It obstructs the downstream signaling and proliferation of these particular cancer cells expressing the FGFR-TACC fusion.

This study will enroll eligible patients into 2 groups, with the first group consisting of patients who are not eligible for surgical resection of their tumor; the second group will consist of patients who will have surgery as part of their routine care. The length of one treatment cycle is 28 days. Those in group one will receive BGJ398 once daily, by mouth on Days 1 to 21. Patients in group 2 will receive BGJ398 once daily for 5-10 days prior to surgery. After surgery, group 2 patients can resume treatment and receive the study drug once daily from Days 1-21 in the 28-day cycle. During each cycle for both groups, various examinations and laboratory tests will be performed.

**NERATINIB**

Another clinical trial focusing on a particular target that may be found in high grade gliomas is a phase 2 study of Neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2 and HER3). This study is sponsored by Puma Biotechnology, Inc. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI). This TKI targets the ErbB receptors: EGFR, HER2, and HER3. Patients with recurrent malignant brain tumors that harbor an EGFR mutation or EGFR gene amplification are eligible for this study, pending agreement with other study eligibility criteria.

EGFR, which is overexpressed in 40-50% of GBM tumors, regulates cell growth and differentiation. Abnormalities in this gene can cause growth of tumor cells. In this phase 2 study, Neratinib will be investigated for its role in treatment of patients with recurrent malignant brain tumors, as well as its role in other solid tumors. Neratinib is a small molecule that binds itself to the ErbB receptors to block the pathway signaling of tumor activity. Previous clinical study of Neratinib on patients with HER2 positive breast cancer resulted in being a reasonably tolerated drug that showed substantial clinical activity. (Harold J. Burstein, Yan Sun, et al., Journal of Clinical Oncology 2010 Mar 10; 28(8): 1301-70). These results have implications for further research into using Neratinib on brain cancer with EGFR (an ErbB family receptor) aberrations.

Patients enrolled in this study will receive the investigational drug by mouth once a day for 28 days, which is the full length of one treatment cycle. Study patients will be asked to come in for clinical assessment visits every 4 weeks (Day 1 of each cycle). Physical and neurological exams, bloodwork, MRI scans, ECGs and ECHOs will be performed during the period the patient is on study.

**AMG-595**

The ADC is designed to deliver a potent anti-EGFR antibody to the tumor. Preclinical studies have shown a positive response to EGFRvIII. UCLA will participate in the study to measure the safety, tolerability and effectiveness of the ADC that is open to adult patients with recurrent malignant gliomas with EGFRvIII expression.

Patients will be pre-screened for eligibility. Those who enroll into the study should expect administration of the study drug via IV infusion once every 3 weeks with frequent visits for physical examinations, neurological evaluations, laboratory testing, EKG tests, MRI scans and study drug dosing.

For more information about these studies and others being offered by UCLA Neuro-Oncology Program, please call Emese Filka at (310) 794-3521.
Research Collaboration Finds Effective Brain Penetrant

Dr. Leia Nghiemphu leads UCLA clinical trial research study on Lapatinib, an EGFRvIII type II inhibitor, for patients with Glioblastoma Multiforme.
The UCLA Neuro-Oncology Program has completed a Pilot study of high-dose pulses of lapatinib (Tykerb, provided by Glaxo-Smith Kline) in combination with regional radiation therapy (RT) and temozolomide (TMZ) chemotherapy for patients with newly diagnosed Glioblastoma (GBM). Lapatinib is a potent inhibitor of the Epidermal Growth Factor Receptor (EGFR).

In brain cancer, the EGFR pathway regulates cell proliferation. Certain genetic alterations exist that can activate the cellular pathway and lead to tumor growth. About 50% of GBM cases can have increased upregulation of EGFR. About half of these can also have a mutation of EGFR, the epidermal growth factor receptor variant III (EGFRvIII), which can lead to permanent activation of this pathway. Lapatinib is designed to inhibit the EGFR receptor to disrupt the cellular pathway and block signaling for cell proliferation.

In collaboration between UCLA Neuro-Oncologists and researchers at Memorial Sloan Kettering Cancer Center, laboratory studies show that Lapatinib (a type II inhibitor) was able to induce cell death better than other first-generation EGFR kinase inhibitors (Type I inhibitor) on GBM cells. Lapatinib was also found to be a more effective brain penetrant when given in higher concentrations for 2-3 days per week than at the levels of standard daily dosing approved for advanced breast cancer treatment. (Igor Vivanco, H. Ian Robins, Daniel Rohle, et al., Cancer Discovery 2012;2:458-471). Based on these findings, Dr. Nghiemphu at UCLA then developed a clinical trial using a novel approach to treating GBM tumors, using pulse doses of Lapatinib.

The initial pilot study in 10 patients found that the combination of high dosages of lapatinib, given 2-days per week only, with RT and TMZ is quite tolerable, with no serious adverse events related to these medications. Based on this safety finding, the UCLA Neuro-Oncology program plans to expand this study to another 40 patients to test its effectiveness in prolonging survival of patients with GBM.

This Phase II trial consists of concurrent, rest and maintenance periods. In the concurrent period, Lapatinib will be given along with standard RT and daily TMZ treatments. This period lasts 42 days, with high concentrations of Lapatinib in tablet form given as pulses for the first two days of each week of concurrent treatment. Blood work and physical exams will be required during this period. Following completion of RT, administration of temozolomide will stop for a rest period of 2-4 weeks. During this rest period, the study drug will be continued for the first two days of each week. In the maintenance phase, TMZ will be restarted on the next planned dose of Lapatinib. TMZ will be given for the first 5 days of a 28-day cycle. Lapatinib will continue for 2 days per week. TMZ and lapatinib can continue for 12-24 cycles, and if no tumor recurrence, lapatinib can be continued as a monotherapy. MRIs of the brain would be obtained every 8 weeks to evaluate for any tumor changes.

To be eligible for the study, patients must be at least 18 years of age and have a Karnofsky Performance Status equal to or greater than 60. Patients must also have histologically proven GBM and must also have available archived tumor tissue from surgery. For details about additional eligibility criteria, please contact the UCLA Neuro-Oncology Program.
IDH1 Mutation Discovery Sparks New Research

UCLA Neuro-Oncology will be opening a ground-breaking trial, A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation. This is a multi-site trial, with a target population consisting of advanced solid tumors including gliomas harboring the IDH1 mutation.

The discovery of the IDH1 in gliomas in 2008 has sparked important new avenues of insight into our understanding of how certain gliomas arise and how they may be treated. Translational patient tissue oriented research conducted in Dr. Lai’s laboratory has contributed to this understanding.

The focus of this trial is based on the discovery by Agios Pharmaceuticals that the IDH1 mutation generates a novel oncometabolite, 2-HG. While the precise mechanism has yet to be worked out, 2-HG is likely to play a critical role in triggering the development of gliomas and influencing their behavior. AG-120 is an oral inhibitor of 2-HG generation by the IDH1 mutant protein.

This trial represents the first-in-man study of the safety and efficacy of AG-120 for the treatment of advanced solid tumors including glioma that harbor an IDH1 mutation. The initial part of this trial will be dose-finding to determine the maximum tolerated dose (MTD). The second part will then look at additional patients with IDH1 mutant gliomas as well as chondrosarcomas, and intrahepatic cholangiocarcinomas.

The trial will enroll patients that have failed standard treatments such as radiation and/or temozolomide or PCV. Overall, 51 patient nationwide are expected to be enrolled, with roughly 12-15 being glioma patients. The key criteria are that patient have had tumors that have been tested for and show the IDH1 mutation and have progressed through standard treatment. IDH1 mutational testing is a routine part of neuropathological evaluation of all glioma patients at treated at UCLA, and can be performed whether or not the patient’s resection occurred at UCLA.

The Lai Lab at UCLA is dedicated to improving outcomes and ultimately finding the cure for patients with primary brain cancer. To find out more about the Lai Lab and its research, visit http://lailab.neurology.ucla.edu/.
## UCLA Neuro-Oncology: Clinical Trials Now Enrolling

For more information about any of the UCLA Neuro-Oncology Program's clinical trials, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521.

<table>
<thead>
<tr>
<th>UCLA IRB#</th>
<th>Study ID#</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-000103</td>
<td>Agios AG120-C-002</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation</td>
</tr>
<tr>
<td>14-000075</td>
<td>Bristol-Myers Squibb CA209143</td>
<td>A Randomized Phase II Open Label Study of Nivolumab or Nivolumab in combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)</td>
</tr>
<tr>
<td>13-001869</td>
<td>PUMA PUMA-NER-S201</td>
<td>An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification</td>
</tr>
<tr>
<td>13-001743</td>
<td>Novartis CBGJ398X2201</td>
<td>A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma</td>
</tr>
<tr>
<td>13-001689</td>
<td>Tocagen Tg S11-13-01</td>
<td>A Phase I Ascending Dose Trial of the Safety and Tolerability of Toca S11, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of Subsequent Resections for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended-Release 5-FC</td>
</tr>
<tr>
<td>12-001647</td>
<td>DFCI (AMG386) 12-185</td>
<td>Phase I/II Study of AMG 386 with or without Bevacizumab for Recurrent Glioblastoma</td>
</tr>
<tr>
<td>12-001146</td>
<td>Novartis CLDE225X2114</td>
<td>A Phase Ib, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>12-000493</td>
<td>Nghiemphu: GSK LAP115352</td>
<td>Phase II Trial of Pulse Dosing of Lapatinib in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme</td>
</tr>
<tr>
<td>11-003531</td>
<td>Amgen 20090505</td>
<td>A Phase I First-in-Human Study Evaluation Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects with Recurrent Malignant Gliomas Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFrVIII)</td>
</tr>
<tr>
<td>11-003527</td>
<td>Genentech GO28070</td>
<td>An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients with Progressive or Recurrent High-Grade Gliomas</td>
</tr>
<tr>
<td>11-003256</td>
<td>Tocagen Tg S11-11-01</td>
<td>A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca S11, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended Release 5-FC</td>
</tr>
<tr>
<td>11-002222</td>
<td>Lai: MLN X05303</td>
<td>Phase II Trial of VECADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme.</td>
</tr>
<tr>
<td>10-000760</td>
<td>Nghiemphu: GNE AVF4535s</td>
<td>Phase II Study of Bevacizumab and Temozolomide in Elderly Patients with Newly-Diagnosed Glioblastoma Multiforme</td>
</tr>
<tr>
<td>10-000484</td>
<td>Tocagen Tg S11-08-01</td>
<td>A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca S11 in Patients with Recurrent High Grade Glioma</td>
</tr>
</tbody>
</table>
On October 5, 2013 brain cancer research donors, supporters, patients and families gathered to celebrate Art of the Brain’s 14th annual gala at UCLA Schoenberg Hall. The fundraising gala is held each year to benefit the advancement of brain cancer research at the UCLA Neuro-Oncology Program.

Brain cancer is a devastating disease that affects the lives of many. According to the Central Brain Tumor Registry of the United States, in 2010 more than 138,054 individuals were living with brain cancer in the United States alone. Part of the mission of Art of the Brain, a non-profit organization under the auspices of The UCLA Foundation, is to raise money to fund research to help these individuals survive this disease, as well as raising brain cancer awareness and spotlight the talent and courage of brain cancer patients.

More than 400 people came together at the 2013 gala, themed “The Art of Healing with Family Traditions,” to show their solidarity in beating brain cancer. Guests were welcomed with a spirited reception featuring live music and a great selection of various cuisines and wines. Participating in the reception were Adelaida Cellars, Barney’s

**SAVE THE DATE!**
Saturday, September 27, 2014
Art of the Brain 15th Anniversary Gala

(Above) Dr. Timothy Cloughesy, President of Art of the Brain, with youth volunteers, Lyric Carlberg and Kyle Spiegelman

JUDI KAUFMAN FOUNDER’S RESPONSIBILITY AWARD
Honored at the Gala’s show was the Lew Weitzman Family. The Weitzman Family was presented with the Judi Kaufman Founder’s Responsibility Award for demonstrating commitment to activities benefiting brain cancer research and treatments. Lew Weitzman had been a long time supporter of Art of the Brain, along with his wife Dale. Lew, who passed away in 2013, was a UCLA alumnus who joined the MCA talent agency after performing military service. He also worked with the William Morris Agency before forming his own, Lew Weitzman and Associates. Weitzman also established Preferred Artists Agency. His career in the entertainment industry had spanned a great number of years where he worked with numerous clients. The award was accepted on behalf of the family by his sons, Matt and Paul.

JOHNNY MERCER FOUNDATION RESEARCH AWARD
Also recognized at the 14th annual gala was Dr. Benjamin Ellingson, Assistant Professor of the UCLA Departments of Radiological Sciences, Biomedical Physics, and Bioengineering. Dr. Ellingson was the recipient of The Johnny Mercer Foundation Research Award for his demonstrated efforts to advance brain cancer research and improve brain tumor imaging techniques.

Dr. Ellingson obtained his PhD in Functional Imaging at Marquette University and the Medical College of Wisconsin. His research interests include image protocol standardization and quality control for multicenter clinical trials in...
brain tumors, imaging biomarkers for novel brain tumor therapies, functional Diffusion Mapping (fDMs) in brain tumors, and voxelwise spatiotemporal modeling of brain tumors using serial imaging, among others. Outcomes of his research have been published in notable scientific journals such as Journal of Neurooncology, Neuro Oncology, and Magnetic Resonance in Medicine.

THE SHOW
To celebrate each honoree, patient, and family who are affected by this disease, the audience was treated to stage performances from Michael Holmes and Cory Hills.

Michael Holmes is known for his production of The Judy Show, a tribute show to Hollywood legend, Judy Garland. Based in Palm Springs, The Judy Show is one of the longest-running cabaret shows in Southern California that also plays to sold-out houses throughout the U.S., Mexico, and Europe. As Judy Garland, Holmes opened the show in vibrant song. Throughout the evening, Holmes continued with crowd-pleasing entertainment, and closed the show with classic song, “Somewhere Over the Rainbow,” offering hope and fostering courage to those facing difficult times.

Cory Hills, an active performer, composer and recording artist in Los Angeles, performed a multiple percussion piece production simulating the sounds of an MRI machine. MRIs are used in follow up care of brain tumor patients. His performance allowed the audience to hear what it is like when patients undergo an MRI scan.

This year’s gala was produced by Patti Lawhon, with the stage show directed by Darith Mackenzie. Jason Barry, a general assignment reporter for the CBS-affiliate in Phoenix, served as Master of Cer-
Barry was also honored at the gala with a recognition award for his many years of commitment to Art of the Brain serving as the gala emcee.

Art of the Brain is a non-profit organization under the auspices of The UCLA Foundation. It was founded in 2000 by international community activist and brain cancer survivor Judi Kaufman, and also by director of the UCLA Neuro-Oncology Program, Dr. Timothy Cloughesy. The mission of the organization is to raise money for the UCLA Neuro-Oncology Program’s brain cancer research, to raise public awareness of the disease, and spotlight the talent, strength and courage of brain cancer patients.

In 2013, Art of the Brain raised $405,114 for brain cancer research.

With the support of volunteers, friends, donors and sponsors, Art of the Brain has raised more than $6.3 million since its inception. With this, the organization has been able to fund important brain cancer research initiatives that have resulted in landmark breakthroughs, leading the world one step closer to a cure. It has also funded the training of several physician-researchers. In addition to fundraising, Art of the Brain offers a support system through their “Brain Buddies” for those individuals that are experiencing a brain cancer diagnosis.

For those who are interested in supporting or becoming involved with Art of the Brain, please visit the Art of the Brain website located at www.artofthebrain.org or call (310) 825-5074.
UCLA 14th Annual Brain Tumor Conference: May 9th & 10th

Join brain tumor survivors, family members, friends and health care professionals at the Fourteenth Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program. This FREE conference will offer participants the opportunity to hear leading healthcare professionals speak about the latest treatments for brain tumors. Attendees will also have a chance to learn about symptom management, community resources and social support. Representatives from brain tumor organizations, health advocacy agencies, and support groups will also be available to offer vital information and resources catering to the brain tumor community.

Free Conference Registration at http://neurooncology.ucla.edu

When: Friday, May 9, 2014
8:00am to 5:00pm
Saturday, May 10, 2014
8:00am to 2:30pm

Where: UCLA Covel Commons
330 De Neve Drive
3rd Floor
Los Angeles, CA

Parking: Parking Structure
Sunset Village (PSV)
*Daily Parking Permit: $12
*Daily Disabled Parking Permit: $5

Directions
- Take the San Diego Freeway (I-405)
- Exit Sunset Blvd EAST
- Head EAST on Sunset Bl, past Veteran Ave
- Turn RIGHT at Bellagio Drive
- Make a LEFT at the stop, and continue down the road; Sunset Village Parking will be on your Right.

*ON FRIDAY, from 7am to 2pm*, purchase a daily parking permit from the attendant stationed at the gate and park in an unrestricted space.
*After 2:00pm*, if paying via credit card or cash, proceed to park in a designated Parking Pay Station space and go to the nearest Parking Pay Station to pay for a permit. If paying via Bruincard (cash also accepted) proceed to the UCLA Information and Parking Kiosk located on Westwood Plaza & Strathmore Drive to purchase a parking pass and park in an unrestricted space in PSV.

*ON SATURDAY, from 7am to 12pm*, purchase a daily parking permit from the attendant stationed at the gate and park at an unrestricted space.
*After 12pm*, if paying via credit card or cash, proceed to park in a designated Parking Pay Station space and go to the nearest Parking Pay Station to pay for a permit. If paying via Bruincard (cash also accepted) proceed to the UCLA Information and Parking Kiosk located on Westwood Plaza & Strathmore Drive to purchase a parking pass and park in an unrestricted space in PSV.

* From parking structure, take elevator to the Lobby level.
* Covel will be directly in front of elevator exit. Follow signage to the conference.
* Once in Covel, take the elevator to 3rd floor.
### Friday, May 9, 2014: General Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Program Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Registration &amp; Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>Welcome Note &amp; Overview of Brain Tumors</td>
<td>Speaker: Timothy F. Cloughesy, M.D.; Director of UCLA Neuro-Oncology Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor, UCLA Department of Neurology</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Neurosurgery Techniques</td>
<td>Speaker: Linda Liau, M.D., Ph.D.; Director of UCLA Neurosurgery Brain Tumor Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor, UCLA Department of Neurosurgery</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Brain Tumor Imaging</td>
<td>Speaker: Benjamin Ellingson, Ph.D.; Assistant Professor, UCLA Departments of Radiological</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sciences, Biomedical Physics and Bioengineering</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Radiation Treatments and Stereotactic Radiosurgery</td>
<td>Speaker: Tania Kaprelian, M.D.; Assistant Professor, UCLA Department of Radiation Oncology</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Chemotherapy &amp; Biological Agents</td>
<td>Speaker: Albert Lai, M.D., Ph.D.; UCLA Neuro-Oncology Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associate Professor, UCLA Department of Neurology</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Understanding Neuropathology</td>
<td>Speaker: William H. Yong, M.D.; Director of UCLA Brain Tumor Translational Resource</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor, UCLA Department of Pathology and Laboratory Medicine</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Experimental Therapies: Agents in Clinical Trials</td>
<td>Speaker: Leia Nghiemphu, M.D.; UCLA Neuro-Oncology Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assistant Professor, UCLA Department of Neurology</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Brain Tumor Translational Resource: Tumor Banking</td>
<td>Speaker: William H. Yong, M.D.; Director of UCLA Brain Tumor Translational Resource</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor, UCLA Department of Pathology and Laboratory Medicine</td>
</tr>
</tbody>
</table>

**PHYSICIAN CONSULT SESSIONS**

(Friday, May 9, 2014 Only)

Participants will also have the opportunity to register for a free, 15-minute consultation with a participating physician specializing in neurooncology, neurosurgery, radiation-oncology or pediatric neurooncology (subject to change). Here is your chance to meet with a physician in a one-on-one setting to ask questions regarding your medical care. Available appointments are limited and only available on Friday, May 9th. Those interested in a consultation should sign up upon arrival at the registration desk. Appointments will not be taken prior to the day of the event.

**HOTEL ACCOMMODATIONS**

There are several hotels in the surrounding area of the conference. The hotels listed below are independent businesses with no affiliation to UCLA Neuro-Oncology Program. We list these accommodations for the convenience of our conference attendees.

- UCLA GUEST HOUSE: (310) 825-2923
- HILGARD HOUSE HOTEL: (310) 208-3945
- UCLA TIVERTON HOUSE: (310) 794-0151
- CLAREMONT HOTEL: (310) 208-5957
- THE W HOTEL: (310) 208-8765
- ROYAL PALACE WESTWOOD: (310) 208-6677
- HOTEL ANGELENO: (310) 475-6411
- HOTEL PALOMAR: (310) 475-8711
Saturday, May 10, 2014: Breakout Sessions

8:00 am  
Registration & Continental Breakfast

9:00 am [SESSION I]:  
A. Tumor-Related Cognitive Difficulties and Best Practices for Cognitive Enhancement  
Speaker: Pia Banerjee, PhD; Neuropsychology Fellow, UCLA Neuro-Oncology Program
What are the common cognitive difficulties that brain tumor patients experience? What can be done to help manage and treat these specific concerns? Learn simple ways of better managing tasks of everyday living involving memory, attention, language, spatial skills, and organization.

B. Legal Issues: Employment & Benefits  
Speaker: Alexis Alvarez; Staff Attorney, Cancer Legal Resource Center
Learn about workplace protections, state fair employment laws, and employment benefits such as Family Medical Leave Act (FMLA) and Disability insurance.

C. Seizure Management  
Speaker: Yoon Choi, MD; Fellow, UCLA Neuro-Oncology Program
History, epidemiology, classifications, causes and risk factors of seizures are discussed. Also find out how to manage seizures and what drugs are used for treatment.

D. Tumor Type: Brain Metastasis  
Speaker: Timothy Cloughesy, MD; Director, UCLA Neuro-Oncology Program
Brain metastases are tumors that have spread to the brain from another primary cancer from other organs such as breast, lung or prostate cancer. A review of brain metastasis and treatment options will be covered.

E. Creative Arts Therapies: An Experiential Panel Presentation  
Moderator: Ping Ho, MA, MPH; Founding Director, UCLArts and Healing
A panel of leading experts from four creative arts therapy disciplines (art therapy, dance/movement therapy, music therapy, and poetry therapy) will offer an experiential demonstration of the principles of their work. A 2013 study published in the Journal of the American Medical Association - Internal Medicine analyzed the outcome of 27 studies of creative arts therapies used with cancer patients and concluded that they were beneficial for reducing anxiety, depression and pain, and improving quality of life. The creative arts therapies offer social, emotional, physical, and cognitive benefits for everyone, including family members and caregivers.

10:00 am [SESSION II]:  
A. Symptom Management  
Speaker: Nanette Fong, RN, MSN, NP; Nurse Practitioner, UCLA Neuro-Oncology
Symptoms from brain tumors and side-effects of associated treatments are discussed. Learn about the causes and side effects of these symptoms, and what you can do to manage them.

B. Integrating Psychosocial Support Into Treatment: “The Patient-Active Approach”  
Facilitator: Bill Kavanagh; Asst. Program Director, Cancer Support Community Benjamin Center
Listen to and interact with a panel of patient survivors who share their experiences of living with a brain tumor, and discover the benefits of social support groups.

C. End of Life Issues  
Speakers: Leia Nghiemphu, MD; UCLA Neuro-Oncology Program  
Cheryl Abe, LCSW; UCLA Oncology Center
Gather information about end of life care for brain tumor patients, what changes to expect at this stage, and information about hospice and palliative care.

D. Understanding Language Impairments  
Speaker: Susan Bookheimer, PhD; Professor, UCLA Psychiatry & Biobavioral Sciences
This session reviews the different types of language impairments and deficits that can occur from brain tumors. Learn about language areas of the brain and the types of problems associated with each when affected by tumors.

E. Tumor-Related Cognitive Difficulties and Best Practices for Cognitive Enhancement [repeat]  
Speaker: Pia Banerjee, PhD; Neuropsychology Fellow, UCLA Neuro-Oncology Program
See description from 9:00am session.

11:00 am [SESSION III]:  
A. Nutrition for Brain Tumor Patients  
Speaker: Carolyn Katzin, MSPH, CNS; Integrative Oncology Specialist, Simms/Mann UCLA Center for Integrative Oncology
What types of foods provide benefits? What food and supplements should you avoid during treatment? Attend this session to learn about brain metabolism and nutrition, barriers to eating healthy and how to manage your diet during treatment and while living with a brain tumor.

B. Helping Children When A Parent Has A Brain Tumor  
Speaker: Kauser Ahmed, PhD; Clinical Psychologist, Simms/Mann UCLA Center for Integrative Oncology
When a parent is diagnosed with a brain tumor, the diagnosis affects the whole family especially his or her child(ren). Discover how to help children understand and cope with their parent's brain tumor.
11:00 am [SESSION III]: C. Navigating Health Insurance
Speaker: Alexis Alvarez; Staff Attorney, Cancer Legal Resource Center
Learn about insurance options, coverage issues and relevant healthcare laws.

D. Coping With Aphasia
Speaker: Joan McCulloch; Sr. Speech Pathologist, UCLA Audiology & Speech Pathology
Aphasia is a speech-language comprehension disorder that can be caused by brain tumors. Find out details about aphasia and what kinds of therapy are available.

E. Qi Gong Exercise
Instructor: Michael Sieverts
Qi gong means “the study of energy.” Participate in this exercise, which is a series of movements and coordinated breathing that is designed to maintain shining health and excellent focus. Learn how to integrate this exercise into recovery.

11:45 am LUNCH

12:45 pm [SESSION IV]: A. Coping with Cancer Fatigue
Speaker: Arash Asher, MD; Director, Cancer Survivorship and Rehabilitation, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Fatigue is one of the most common, troubling symptoms of cancer and cancer treatment. Causes for this problem and strategies to cope are discussed, including ways to improve your sleep and safely integrate exercise into your routine.

B. Mindfulness as Medicine
Speaker: Lisa Kring, LCSW; Clinical Consultant, Simms/Mann UCLA Center for Integrative Oncology
Discover mindfulness meditation and how to practice this technique to cultivate peace and balance in everyday life. Learn about the benefits that mindfulness meditation has for cancer patients.

C. Understanding Clinical Trials
Speaker: Stacey Green, RN, MSN, NP; Nurse Practitioner, UCLA Neuro-Oncology
Find out what a clinical trial is, why it is conducted and the pros and cons of participating in a trial. For those interested in learning about the latest trials, please also attend the general session on Friday, May 9th “Experimental Therapies: Agents in Clinical Trials”

D. Understanding the Family Experience
Facilitators: Cheryl Abe, LCSW; UCLA Oncology Center & Pam Hoff LCSW, UCLA Radiation Oncology
Listen to a panel of family members sharing their experiences with brain tumors and how they have managed to cope with the effects it has had on their family lives.

E. Nutrition for Brain Tumor Patients (repeat session)
Speaker: Carolyn Katzin, MSPH, CNS; Integrative Oncology Specialist, Simms/Mann UCLA Center for Integrative Oncology
See description on previous page

1:45pm [SESSION V]: A. Tumor Type: Glioblastoma Multiforme & Anaplastic Tumors
Speaker: Timothy Cloughesy, MD; Director, UCLA Neuro-Oncology Program
An in-depth look at treatment options for GBM and Anaplastic Astrocytoma is presented. Learn about first line and recurrent treatments, molecular biomarkers, clinical outcomes, targeted therapies, and the latest on clinical research trials for GBM/AA tumors.

B. Tumor Type: Low Grade Tumors & Oligodendrogliomas
Speaker: Albert Lai, MD, PhD; UCLA Neuro-Oncology Program
Get a closer look at low grade gliomas, including oligodendrogliomas. Epidemiology, treatment options and future directions for these tumor types are discussed.

C. Tumor Type: Meningiomas
Speaker: Richard Green, MD; Director, Neuro-Oncology at Kaiser Permanente Los Angeles
This lecture will cover the history, pathology and the different classifications of meningioma. Symptoms, standard treatment options and clinical trials for this specific diagnosis will also be covered.

D. Tumor Type: Pediatric Brain Tumors
Speaker: Tom Davidson, MD; Assistant Clinical Professor, UCLA Dept of Pediatric Hematology-Oncology and Director, UCLA Pediatric Neuro-Oncology
Learn about brain tumors that affect children and adolescents and how they can be treated.

E. Tumor Type: Rare Tumors
Speaker: Leia Nghiemphu, MD; UCLA Neuro-Oncology Program
Brain tumors such as Medulloblastoma, Ependymoma, CNS lymphoma, pineal region tumors, and germ cell tumors (among others) will be addressed in a “Question and Answer” format.
UCLA Brain Tumor Conference
Registration

Registration by fax and online must be submitted by Tuesday, May 6, 2014. Registration by mail must be postmarked by Saturday, May 3, 2014.

QUESTIONS - Please call (310) 206-3610 or email at neuroonc@ucla.edu

***If registering family members or companions, please complete a separate registration form for each attendee.

FIRST & LAST NAME __________________________________________________________________________________________
I AM A: [ ] patient [ ] caregiver [ ] family member [ ] healthcare professional [ ] other: ___________________________
ADDRESS __________________________________________________________________________________________________
CITY ______________________________________________  STATE _______________  ZIP CODE __________________________
TELEPHONE/MOBILE PHONE # __________________________________  FACSIMILE # __________________________________
EMAIL ADDRESS _____________________________________________________________________________________________

PLEASE INDICATE WHICH SESSION(S) YOU PLAN TO ATTEND FOR EACH DAY

FRIDAY, MAY 9, 2014  GENERAL SESSIONS
[ ] 9:00 am Welcome & Overview of Brain Tumors  [ ] 10:00 am Neurosurgery Techniques
[ ] 11:00 am Brain Tumor Imaging  [ ] 1:00 pm Radiation Treatments & Stereotactic Radiosurgery
[ ] 2:00 pm Chemotherapy & Biological Agents  [ ] 3:00 pm Understanding Neuropathology
[ ] 3:45 pm Experimental Therapies  [ ] 4:30 pm Brain Tumor Banking

SATURDAY, MAY 10, 2014  BREAKOUT SESSIONS (please choose ONLY ONE from each session)
SESSION I - 9:00 am  [ ] A. Tumor-Related Cognitive Difficulties  [ ] B. Employment & Benefits
[ ] C. Seizure Management  [ ] D. Tumor Type: Brain Metastasis
[ ] E. Creative Arts Therapy
SESSION II - 10:00 am  [ ] A. Symptom Management  [ ] B. Integrating Psycho-Social Support
[ ] C. End of Life Issues  [ ] D. Understanding Language Impairments
[ ] E. Tumor-Related Cognitive Difficulties [repeat]
SESSION III - 11:00 am  [ ] A. Nutrition  [ ] B. Helping Children When A Parent Has A Brain Tumor
[ ] C. Navigating Health Insurance  [ ] D. Coping With Aphasia
[ ] E. Qi Gong Exercise
SESSION IV - 12:45 pm  [ ] A. Coping With Cancer Fatigue  [ ] B. Mindfulness as Medicine
[ ] C. Understanding Clinical Trials  [ ] D. Understanding the Family Experience
[ ] E. Nutrition [repeat]
SESSION V - 1:45 pm  [ ] A. GBM/Anaplastic Tumors  [ ] B. Low Grade & Oligos
[ ] D. Pediatric Brain Tumors  [ ] E. Rare Tumors
[ ] C. Meningiomas

DO YOU REQUIRE A VEGETARIAN MEAL?   [ ] yes  [ ] no
DO YOU REQUIRE SPECIAL ASSISTANCE?   [ ] yes  [ ] no  Please Specify: ____________________________
ARE YOU CURRENTLY RECEIVING TREATMENT AT UCLA?   [ ] yes  [ ] no
HOW DID YOU HEAR ABOUT THIS CONFERENCE? __________________________________________________________
Without the support of its generous donors, the UCLA Neuro-Oncology Program would not be able to make accelerated advancements in brain cancer research. The UCLA Neuro-Oncology Program would like to express its heartfelt thanks to the families and friends of those listed below who have supported its brain cancer research efforts. For information about making a contribution or creating a memorial fund, please call the UCLA Neuro-Oncology Program office at (310) 206-3610.
UCLA 14th Annual Brain Tumor Conference
May 9th & May 10th, 2014

Join brain tumor survivors, family members, friends and health care professionals at the 14th Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program.

Registration Deadline: May 6, 2014

FREE Conference Registration at http://neurooncology.ucla.edu